NEW! Investment Companies Centre
Virgin Credit Card:
£1.58m
0.000p ()
0.36p
Healthcare Enterprise Group plc
("HCEG", "the Company" or "the Group")
Total Voting Rights
Director/PDMR Shareholding
The Board of Healthcare Enterprise Group plc (AIM: HCEG), a company engaged in the sale and distribution of patented cleaning and decontamination products and medical devices product development, announces that, pursuant to the notification made on 18 September 2008 and following the placing of 100,000,000 Ordinary Shares of 0.1p ("Ordinary Shares"), to institutional and other investors, the Company's total issued share capital comprises 439,099,622 Ordinary Shares of 0.1p each, with voting rights. The Company does not hold any shares in Treasury.
The above figure of 439,099,622 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in Healthcare Enterprise Group plc under the FSA's Disclosure and Transparency Rules.
Following today's admission of shares, the Directors' interests (either directly or indirectly) in Ordinary Shares and Options are set out below:
|
Name: |
Total Ordinary Shares: |
Total Ordinary Shares - % of the current issued share capital: |
Total Options: |
|
Mark Tompkins, Non Executive Chairman |
4,681,583 |
1.07 |
6,054,766 |
|
Lyndon Gaborit, Executive Deputy Chairman |
1,303,351 |
0.30 |
10,706,647 |
|
Nicholas Brigstocke, Non Executive Director |
6,156,968 |
1.40 |
2,417,696 |
|
Gron Ffoulkes-Davies, Group Finance Director |
1,250,000 |
0.28 |
3,000,000 |
|
John Gunn, Non Executive Director |
41,140,581 |
9.37 |
0 |
Further Enquiries:
Healthcare Enterprise Group Plc
Lyndon Gaborit, Executive Deputy Chairman Tel: + 44 (0)1925 898 200
Daniel Stewart & Company Plc
Lindsay Mair/Stewart Dick/Tessa Smith Tel: + 44 (0) 207 776 6550
Notes to Editor:
Healthcare Enterprise Group PLC companies include Ebiox Limited, a specialist disinfectant and decontamination company which has a range of proprietary products patented and approved for sale in multiple world markets; Reproductive Sciences Limited which invests in medical devices product development, particularly in the area of women's' health; and investments in healthcare products and services.